PCI Pharma Services ("PCI" or the "Company"), a world-leading global contract development and manufacturing organization ...

PCI Pharma Services has received a strategic investment co-led by Bain Capital and existing lead investor Kohlberg, and ...

Mubadala’s investment is part of a strategic transaction co-led by Bain Capital and existing lead investor Kohlberg ...

The firms lead an investment valuing PCI Pharma at $10 billion, see the company benefiting from broader trends.

PCI Pharma Services, a Philadelphia-based biotherapy-focused contract development and manufacturing organization, has secured an investment co-led by Bain Capital and existing backer Kohlberg.

The CDMO, which has been owned by different private investors over the last decade, will use the funds to broaden its geographic reach.

Business & Finance ...

A Philadelphia-based pharmaceutical services company has just received a massive investment from two major private equity firms, reportedly catapulting its valuation to $10 billion.

The buyout firm is in discussions with PCI's backers — Kohlberg & Co, Mubadala Investment Co and Partners Group Holding AG — about a deal for a majority stake of the Philadelphia-based drug ...

Mubadala Investment Company, the Abu Dhabi-based sovereign wealth fund managing a global portfolio, is making a significant reinvestment in PCI Pharma Services (PCI).

Bain Capital is in talks to buy contract drug manufacturer PCI Pharma Services at a valuation of $10 billion, Bloomberg News reported on Friday, citing people familiar with the matter.

The buyout firm is in discussions with PCI's backers — Kohlberg & Co, Mubadala Investment Co and Partners Group Holding AG — about a deal for a majority stake of the Philadelphia-based drug ...